About Prof. Jean PierreSummary Of Present WorkHis interest is directed towards therapeutic nanoparticle-based strategies that do not rely on the “Enhanced Permeability and Retention” effect. Among them, the design of various implants including intracerebral systems is currently achieved. In parallel, the targeting of a particular subset of immune cells, the monocytic myeloid-derived suppressor cells (M-MDSC),…
About Prof. Martin MichelMartin C. Michel, MD, underwent post-doctoral training in experimental and clinical pharmacology at the University of Essen (1985-1987 and 1990-1993) and at the University of California San Diego (1987-1990). He was Head of the Nephrology and Hypertension Research Laboratory at the University of Essen (1993-2002), Professor and Head of the Department of…
About Dr. Thamir M. AlshammariPositionsRPh, Ph.D., M.S Advisor, Saudi Food and Drug Authority Executive President. Associate Professor of Pharmacy Practice. Senior researcher, Medication Safety Research Chair, King Saud University. Vice-President, International Society of Pharmacovigilance Middle East Pharmacoepidemiology and Pharmacovigilance Consultant View Full CV.
About Prof. Salwa Ahmed ElgebalyCurrent positionDr. Salwa Elgebaly is the founder and Chief Executive Officer (CEO) of the Biotech Company Nour Heart, Inc. established in Hartford, CT. The aim of the Company is to develop the new cardioprotective drug Cyclocreatine Phosphate for patients with ischemic heart diseases and the cardiac-derived inflammatory mediator Nourin as an…